Prostate-specific G-protein-coupled receptor collaborates with loss of PTEN to promote prostate cancer progression

Oncogene

Volumn 35, Issue 9, 2016, Pages 1153-1162

  Rodriguez, M ^a   Siwko, S ^a   Zeng, L ^a   Li, J ^b   Yi, Z ^b   Liu, M ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROBASIN; PROSTATE SPECIFIC G PROTEIN COUPLED RECEPTOR; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; OLFACTORY RECEPTOR; OR51E2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR INVASION; ANIMAL; BIOSYNTHESIS; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; OLFACTORY RECEPTOR; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CADHERINS; CARCINOGENESIS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ODORANT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84959536401     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.170     Document Type: Article

References (40)

1. Giles GG. Epidemiological investigation of prostate cancer. Methods Mol Med 2003; 81: 1-19.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-381.
3. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685.
4. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod Pathol 2008; 21: 1451-1460.
5. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997; 57: 4997-5000.
6. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967-2000.
7. Shen MM, Abate-Shen C. Pten inactivation and the emergence of androgenindependent prostate cancer. Cancer Res 2007; 67: 6535-6538.
8. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A et al. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003; 1: E59.
9. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7: 1745-1762.
10. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 619-624.
11. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
12. Weng J, Wang J, Cai Y, Stafford LJ, Mitchell D, Ittmann M et al. Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer 2005; 113: 811-818.
13. Xia C, Ma W, Wang F, Hua S, Liu M. Identification of a prostate-specific G-protein coupled receptor in prostate cancer. Oncogene 2001; 20: 5903-5907.
14. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA et al. PSGR, a novel prostate-specific gene with homology to a G proteincoupled receptor, is overexpressed in prostate cancer. Cancer Res 2000; 60: 6568-6572.
15. Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W et al. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 56-61.
16. Weng J, Ma W, Mitchell D, Zhang J, Liu M. Regulation of human prostate-specific G-protein coupled receptor, PSGR, by two distinct promoters and growth factors. J Cell Biochem 2005; 96: 1034-1048.
17. Rodriguez M, Luo W, Weng J, Zeng L, Yi Z, Siwko S et al. PSGR promotes prostatic intraepithelial neoplasia and prostate cancer xenograft growth through NF-kappaB. Oncogenesis 2014; 3: e114.
18. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9: 166-180.
19. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-243.
20. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-816.
21. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66: 4011-4019.
22. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 2003; 63: 3877-3882.
23. Wang J, Weng J, Cai Y, Penland R, Liu M, Ittmann M. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate 2006; 66: 847-857.
24. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
25. Russell PJ, Kingsley EA. Human prostate cancer cell lines. Methods Mol Med 2003; 81: 21-39.
26. MacKenzie L, McCall P, Hatziieremia S, Catlow J, Adams C, McArdle P et al. Nuclear factor kappaB predicts poor outcome in patients with hormone-naive prostate cancer with high nuclear androgen receptor. Hum Pathol 2012; 43: 1491-1500.
27. McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY et al. NFkappaB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer 2012; 107: 1554-1563.
28. Sanz G, Leray I, Dewaele A, Sobilo J, Lerondel S, Bouet S et al. Promotion of cancer cell invasiveness and metastasis emergence caused by olfactory receptor stimulation. PLoS One 2014; 9: e85110.
29. Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. J Mol Endocrinol 2015; 54: R15-R29.
30. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 2008; 105: 12188-12193.
31. Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK et al. Regulation of androgen action. Vitam Horm 1999; 55: 309-352.
32. Cano P, Godoy A, Escamilla R, Dhir R, Onate SA. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res 2007; 67: 511-519.
33. Wikstrom P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009; 69: 799-809.
34. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100-117.
35. Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 2003; 107: 1-10.
36. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM et al. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 2008; 105: 12182-12187.
37. Lai KP, Yamashita S, Huang CK, Yeh S, Chang C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol Med 2012; 4: 791-807.
38. Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2014; 23: 847-856.
39. Kwon OJ, Zhang L, Ittmann MM, Xin L. Prostatic inflammation enhances basal-toluminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci USA 2014; 111: E592-E600.
40. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK et al. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175: 489-499.